Earnings call transcript: Moderna Q1 2026 revenue beats expectations

Moderna reported Q1 2026 revenue of $400 million, well above expectations, driven by strong international sales that accounted for about 80% of revenue. The quarter was weighed down by a $950 million litigation settlement charge and a larger-than-expected $3.40 EPS loss, but shares still rose 3.13% premarket on better revenue and pipeline progress. Management reiterated up to 10% full-year 2026 revenue growth and highlighted EU approval of mCOMBRIAX as a future growth driver.

Analysis

The key signal is not the headline beat; it’s that revenue is increasingly becoming a function of contract timing and geography rather than durable end-demand in the core U.S. franchise. That makes the quarter look better than the underlying run-rate, because a single large overseas delivery can flatter growth while leaving next-quarter visibility thin. The market is rewarding optionality, but the cash-flow bridge still depends on whether international placements roll into repeatable, multi-season demand rather than one-off procurement cycles.

The litigation overhang is more important than the reported loss. Even if the large settlement is already in the numbers, the possibility of an additional payment creates a hidden contingent liability that can cap multiple expansion and keep balance-sheet investors cautious. In practice, that means the stock can trade well on product headlines, but any rally is vulnerable to de-rating if legal developments or guidance revision force investors to focus on residual cash burn and the 2027 cash trough.

The more interesting second-order effect is competitive: a combination respiratory vaccine, if reimbursed well in Europe, could pressure smaller respiratory players and even incumbent adult-vaccine franchises by bundling convenience into procurement decisions. But the adoption curve is likely slower than bulls want, because payer value realization and channel execution matter more than approval. The near-term catalyst stack is strong, yet the stock likely needs confirmation that 2H international demand and the flu readout convert into repeated revenue, otherwise this remains a trading vehicle rather than a compounding biotech story.

Contrarian take: consensus is over-weighting the pipeline and under-weighting how much of the equity value is still tied to managing a shrinking legacy base while funding multiple shots on goal. If the upcoming data disappoints even modestly, the stock can re-rate quickly because expectations have already moved from survival to platform re-acceleration.

Key Decisions for Investors

• Buy MRNA on pullbacks near the post-earnings support level for a 3-6 month trade, but only with a hard stop below the prior breakout zone; the upside is another pipeline-driven re-rating, while the downside is sharp de-rating if Q2 confirms a weak run-rate.
• Pair trade: long MRNA / short a basket of slower-moving vaccine names with less pipeline optionality over the next 6-12 months; this isolates the value of regulatory and oncology catalysts while hedging broad sector multiple compression.
• Consider selling covered calls against a core MRNA position into pre-catalyst strength; implied volatility should stay bid, and the legal overhang makes upside gaps harder to sustain than option pricing suggests.
• Avoid chasing the stock ahead of the next two catalyst windows (Q2 print and early clinical readouts); use any rally above recent premarket highs to trim, since the most likely failure mode is guidance disappointment rather than a single catastrophic event.
• For event-driven accounts, structure a call spread in MRNA into the flu PDUFA and later oncology data to capture upside from successful readouts while limiting theta decay if the market starts discounting the legal and reimbursement lag.